BOULDER, Colo., Dec. 4 /PRNewswire-FirstCall/ -- Pharmion Corporation today announced that the Company will host an Investor and Analyst Event on Monday, December 10 from 7:30 to 9:00pm Eastern time at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH) in Atlanta.
The meeting will provide investors and analysts with the insights and perspectives of U.S. and European physicians regarding Pharmion’s commercial and pipeline products. Members of the Pharmion management team will also participate in the product discussions.
The event will be webcast live and will be accessible via the Pharmion website at http://www.pharmion.com.
About Pharmion
Pharmion is a leading global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world’s first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company’s website at http://www.pharmion.com.
CONTACT: Breanna Burkart, Director, Investor Relations and Corporate
Communications, +1-720-564-9144, bburkart@pharmion.com, or Anna Sussman,
Director, Investor Relations and Corporate Communications, +1-720-564-9143,
asussman@pharmion.com, both of Pharmion Corporation
Web site: http://www.pharmion.com/
